Peptide Treatment Eased Macular Degeneration in Studies
Researchers found that the collagen-derived peptide EB-203 reduced vascular leakage in laboratory models.
Updated on Sept. 30, 2026 in Biotech
Live Poll
Would you prefer using eye drops over injections for treating chronic eye conditions?
A new study evaluated the collagen-derived peptide EB-203 as a potential treatment for neovascular age-related macular degeneration. The peptide showed a significant ability to inhibit vascular growth and leakage in mouse models.
Why it matters
Current treatments for neovascular AMD rely on frequent, invasive intravitreal injections that carry high costs and complication risks. EB-203 offers a potential alternative that could mitigate these clinical burdens.
Mouse models received an intravitreal injection dosage of 100 µg or twice-daily topical eyedrops at 5% or 10% concentrations of EB-203. The peptide successfully reduced the expression of HIF-1α and VEGF proteins in cellular testing.
The players
EB-203
This is a collagen-derived peptide currently being investigated as a therapeutic candidate for neovascular age-related macular degeneration.
The details
The study utilized EA.hy926 cells treated with cobalt chloride to mimic hypoxic conditions, where EB-203 inhibited the migration and invasion of endothelial cells. Researchers observed that the peptide specifically targets proteins associated with choroidal neovascularization, a primary driver of vision loss in neovascular AMD.
Timeline
The findings regarding EB-203 were published on September 30, 2026.
The Big Picture
This research follows a pattern set by the development of anti-VEGF therapies for retinal diseases. It suggests a shift toward non-invasive peptide-based alternatives to replace standard injection-based treatment protocols.
If clinical trials prove successful, patients could eventually benefit from topical eyedrops instead of frequent eye injections. This transition would significantly reduce the physical discomfort and high healthcare costs currently associated with chronic eye treatment.
The takeaway
The study represents a promising step toward simplifying the treatment process for those suffering from macular degeneration. Future research must determine if these initial results can be replicated in human subjects to provide a reliable, less invasive care standard.
Further reading
For more on emerging therapies in the field, explore the Biotech section.
More information
Review the full findings in the peer-reviewed research article published in Nature.
Source note: This article includes information reported by Nature.
Live Poll
Would you prefer using eye drops over injections for treating chronic eye conditions?
